In vitro lipolysis of human VLDL: Effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia 1

Atherosclerosis

Volumn 121, Issue 1, 1996, Pages 75-84

  Van Barlingen, Harrold H J J ^a   Kock, Lucienne A W ^a   De Man, Frits H A F ^a   Erkelens, D Willem ^a   De Bruin, Tjerk W A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Apolipoproteins; Familial combined hyperlipidemia; Familial hypertriglyceridemia; Lipoprotein lipase; VLDL substrate kinetics

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FAMILIAL DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEINS; CATTLE; CELL-FREE SYSTEM; CHOLESTEROL; HUMANS; HYDROLYSIS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE IV; KINETICS; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; PHOSPHOLIPIDS; SUBSTRATE SPECIFICITY; TRIGLYCERIDES;

EID: 0030030689     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05703-X     Document Type: Article

References (47)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG, Campbell ED, Levinski MJ. Hyperlipidemia in coronary heart disease. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544.
2. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipidemia: evidence for a new lipoprotein phenotype. Am J Med 1973;54:148.
3. Nikkilä EA, Aro A. Family study of lipids and lipoprotein in coronary heart disease. Lancet 1973;1:954.
4. Castro Cabezas M, de Bruin TWA, Erkelens DW. Familial combined hyperlipidemia: 1973-1991. Neth J Med 1992;40:83.
5. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arteriosclerosis Thromb 1992;12:1176.
6. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apo B overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arteriosclerosis Thromb 1993;13:1110.
7. Rauh G, Schuster H, Müller B, Schewe S, Keller C, Wolfram G, Zöllner N. Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia. Atherosclerosis 1990;83:81.
8. Jarvik GP, Brunzell JD, Austin MA, Krauss RM, Motulsky AG, Wijsman E. Genetic predictors of FCHL in four large pedigrees: influence of apo B level, major locus predicted genotype and LDL subclass phenotype. Arteriosclerosis Thromb 1994;14:1687.
9. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apo B secretion. Arteriosclerosis Thromb 1993;13:629.
10. Sniderman A, Brown G, Steward BF, Cianflone K. From familial combined hyperlipidemia to hyperapo B: unraveling the overproduction of hepatic apolipoprotein B. Curr Opin Lipidoi 1992;3:137.
11. Castro Cabezas M, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic overproduction and insulin resistance. J Clin Invest 1993;92:160.
12. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203.
13. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147.
14. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds). The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989;6:1165.
15. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apoprotein C-II. N Engl J Med 1978;298:1265.
16. Heliö T, Palotie A, Sane T, Tikkanen MJ, Kontula K. No evidence for linkage between familial hypertriglyceridemia and apolipoprotein B, apolipoprotein C-III or lipoprotein lipase genes. Hum Genet 1994;94:271.
17. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation 1995;91:505.
18. Castro Cabezas M, de Bruin TWA, Jansen H, Kock LAW, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arteriosclerosis Thromb 1993;13:804.
19. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic disease. N Engl J Med 1989;320:1060.
20. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287.
21. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart J, Wang C. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995.
22. Catapano AL. The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects. Atherosclerosis 1980;35:419.
23. Erkelens DW, Mocking JAJ. The CII/CIII ratio of transferable apolipoprotein in primary and secondary hypertriglyceridemia. Clin Chim Acta 1982;121:59.
24. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889.
25. De Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994;269:2324.
26. Brunzell JD, Hazzard WR, Porte DJ, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973;52:1578.
27. Dallinga-Thie GM, van Linde-Sibenius Trip M, Kock LAW, de Bruin TWA. Apolipoprotein E2/E3/E4 genotyping with agarose gels. Clin Chem 1995;41:73.
28. Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem 1975;65:42.
29. Posner I, Wang C, McConathy WJ. The comparative kinetics of soluble and heparin-Sepharose-immobilized bovine lipoprotein lipase. Arch Biochem Biophys 1983;226:306.
30. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206.
31. Itakura K, Matsudate T, Sakurai T, Hashimoto S, Ito K, Kanno H, Hirata M, Nakamura K. Single radial immunodiffusion of serum apolipoproteins C-II, C-III and E pretreatment of samples with surfactant. Clin Chim Acta 1986;161:275.
32. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1993;4:187.
33. Slyper AH. A fresh look at the atherogenic remnant hypothesis. Lancet 1992;340:289.
34. Swenson TL. Transfer proteins in reverse cholesterol transport. Curr Opin Lipidol 1992;3:67.
35. Tatò F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arteriosclerosis Thromb 1995;15:112.
36. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 1989;9:326.
37. Williams KJ, Petrie KA, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. J Clin Invest 1991;88:1300.
38. Karathanasis SK. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII and AIV genes. Biochemistry 1985;82:6374.
39. Nevin DN, Brunzell JD, Deeb SS. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arteriosclerosis Thromb 1994;14:869.
40. Hayden MR, Kastelein JJ, Funke H, Brunzell JD, Ma Y. Phenotypic variation of mutations in the human lipoprotein-lipase gene. Biochem Soc Trans 1993;21:506.
41. Santamarina-Fojo S and Brewer HB Jr. The familial hyperchylomicronemia syndrome, new insights into underlying genetics defects. J Am Med Assoc 1993;265:904.
42. Castro Cabezas M, de Bruin TWA, Kock LAW, Kortlandt W, van Linde-Sibenius Trip M, Jansen H, Erkelens DW. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:497.
43. Brown V and Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochim Biophys Acta 1973;46:375.
44. Krauss RM, Herbert PN, Levy RI, Fredrickson DS. Futher observations on the activation and inhibition of lipoprotein lipase by apoproteins. Circ Res 1973;33:403.
45. Jackson RL, Tajima S, Yamamura T, Yokoyama S, Yamamoto A. Comparison of apolipoprotein C-II deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphotidylcholine-stabilized particles as substrates for lipoprotein lipase. Biochim Biophys Acta 1986;875:211.
46. Yasushi I, Breslow JL, Chait BT. Apolipoprotein C-III0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res 1992;30:1781.
47. Ji Z-S, Fazio S, Lee Y-L, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans Biol Chem 1994;269:2764.